Isofol Medical (ISOFOL) Q2 2026 earnings summary

Executive summary

• Advanced clinical development of arfolitixorin, with phase Ib dose escalation completed and phase II initiation planned before year-end.

• Regulatory approval in Germany for optimized study design, broadening inclusion criteria and enabling direct comparison with standard folate-based therapy.

• Strengthened collaboration with Solasia Pharma K.K. for parallel patient recruitment in Japan.

• Enhanced visibility through participation in major oncology and investor events.

Financial highlights

• Net revenue was SEK 0 for both the quarter and first half, unchanged year-over-year.

• Operating loss for Q2 was SEK -16.3 million, up from SEK -15.0 million in Q2 2025; H1 operating loss was SEK -31.9 million, up from SEK -29.1 million.

• Result after financial items for Q2 was SEK -15.7 million (Q2 2025: -14.7 million); H1 result was SEK -30.8 million (H1 2025: -28.3 million).

• Cash and cash equivalents at June 30, 2026 were SEK 114.8 million, up from SEK 65.7 million a year earlier.

• Equity at June 30, 2026 was SEK 95.0 million (June 30, 2025: SEK 49.6 million).

Outlook and guidance

• Phase II of the arfolitixorin study is expected to begin before the end of 2026, with expanded study centers across Europe and Japan.

• Management believes current funding is sufficient for planned operations over the next 12 months.